Patients with COVID-19 showed lower expression levels of lymphocyte surface CD markers during the first week for all the examined T subsets (CD2, CD4, CD8, CD158d, and CD25) as well as CD127 and B-cell marker CD19 compared to HCs (p < 0.001 for all; Table 2). This evidence concerns the gene IL7R and COVID-19.